header advert
Results 1 - 2 of 2
Results per page:
Applied filters
Include Proceedings
Dates
Year From

Year To
Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_II | Pages 297 - 297
1 May 2010
Gavras G Babis G Zoubos A Soucacos P
Full Access

The purpose of this study was to evaluate the clinical and radiological findings in patients with avascular necrosis of the femoral head after implantation of a porous tantalum implant combined with autologous growth factors (AGF).

The study included 40 hips in 30 patients. Of the 40 hips, 1 hip was stage I, 9 hips were stage II, 22 hips were stage III, and 8 hips were stage IV, according to the Steinberg classification system. Follow-up was 2 to 4 years. The porous tantalum (diameter of 10 mm, length ranging from 70 –110 mm) was implanted in the center of the necrotic area under fluoroscopic control.

Clinical evaluation using the Harris hip score showed an increase from 66 to 96 points preoperatively to postoperatively in hips with stage II disease, from 60 to 85 points in hips with stage III, and from 60 to 80 points in hips with stage IV (p< 0,001). Of the 40 hips, the radiological stage in 20 hips (50%) remained stable, 17 (42.5%) progressed to an advanced stage and 3 hips (7.5%) underwent total hip arthroplasty (p< 0,001). Of the 17 hips that progressed, 7 were stage II, 7 were stage III, and 3 were stage IV. No material damage or implant migration was observed.

Although failures are still observed with the use of porous tantalum, the minimal invasive technique and short operative time make tantalum a reasonable alternative in the treatment of AVN of the femoral head.


Orthopaedic Proceedings
Vol. 92-B, Issue SUPP_II | Pages 308 - 308
1 May 2010
Payatakes A Gavras G Babis G Soucacos P
Full Access

The purpose of this study was to compare the clinical and radiological findings in patients with avascular necrosis of the femoral head after management with vascularized fibular graft (VFG) compared to porous tantalum implant.

The study included 60 hips in 50 patients, who were followed prospectively for 2–4 years. 28 patients (30 hips) were treated with VFG and 22 patients (30 hips) were treated with a porous tantalum implant. The two patient groups were matched for age, gender, etiology, pre-operative stage and Harris Hip Score (HHS). Of the VFG group, 14 hips were stage II and 16 were stage III, while of the tantalum group, 1 hip was stage I, 11 hips were stage II and 18 hips were stage III, according to Steinberg classification system. Mean operative time was 3 hours for VFG and 30 min for porous tantalum.

At final follow-up, there was no significant statistical difference in the radiological stage (p=0.246), and radiological progression of the disease (p=0.329) was observed between these two groups. Using HHS, the mean clinical results improved in the VFG group from 61 points preoperatively to 90 points at final follow-up, while in tantalum group HHS improved from 63 to 81 points (p=0.022). Three hips from each group underwent total hip arthroplasty.

The results of the present study suggest that although the management of AVN with VFG appears to show better results compared to the use of porous tantalum using clinical evaluation Methods: (eg HHS), further controlled studies with larger patient groups and longer follow-up are required.